Search Results

You are looking at 51 - 60 of 72 items for :

  • Refine by Access: All x
Clear All
Full access

Peter L. Greenberg

marrow cells . Blood 1996 ; 88 : 4275 – 4287 . 28. Raza A Mundle S Iftikhar A . Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis

Full access

Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Barker, William E. Carson III, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Morganna Freeman, Anjela Galan, Brian Gastman, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Sameer Nath, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeffrey Sosman, Susan M. Swetter, Kenneth K. Tanabe, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh

maximum treatment duration). 55 Results of KEYNOTE-006 support the recommendation that pembrolizumab should be considered as first-line therapy in patients with unresectable or distant metastatic disease. Anti-PD-1 Agents: Kinetics of Response to

Full access

Mauro P. Avanzi and Renier J. Brentjens

or treat EBV-related lymphoproliferative disease in transplant recipients . Blood 2010 ; 115 : 925 – 935 . 11. Zhao Z Condomines M van der Stegen SJ . Structural design of engineered costimulation determines tumor rejection kinetics and

Full access

Farhad Ravandi and Jeffrey L. Jorgensen

may contribute to postinduction treatment stratification . Blood 2001 ; 98 : 1746 – 1751 . 21 Buccisano F Maurillo L Gattei V . The kinetics of reduction of minimal residual disease impacts on duration of response and survival of

Full access

Andrew K. Lee and Christopher L. Amling

chain of outcomes: Clinical factors (T-stage, biopsy Gleason score, pretreatment PSA) → Pathologic end points (prostatectomy T-stage and Gleason score, margin status, nodal involvement) → Post-treatment end points (time to PSA failure, PSA kinetics

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

Lonial S Waller EK Richardson PG . Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma . Blood 2005 ; 106 : 3777 – 3784 . 67 Zappasodi P Dore R Castagnola C . Rapid response to

Full access

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Timothy M. Kuzel, Richard J. Lee, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Edward Schaeffer, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, and Maria Ho

reclassification at a median follow-up of 2.9 years. 55 Unfortunately, neither PSA doubling time (area under the curve [AUC], 0.59) nor PSA velocity (AUC, 0.61) was associated with prostate biopsy reclassification. Both groups have concluded that PSA kinetics

Full access

Elena Elimova, Roopma Wadhwa, Hironori Shiozaki, Kazuki Sudo, Jeannelyn S. Estrella, Brian D. Badgwell, Prajnan Das, Aurelio Matamoros Jr, Shumei Song, and Jaffer A. Ajani

resistance. It was shown that the SHH signaling was extensively activated in esophageal cancer cells and residual tumors after chemoradiotherapy, and the temporal kinetics of SHH signaling preceded increases in proliferation biomarker expression and tumor

Full access

Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler, and Jane N. Winter

quantitative PCR—initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse . Leuk Res 2006 ; 30 : 389 – 395 102 Paschka P Marcucci G Ruppert AS . Adverse prognostic

Full access

Stephen Harnicar

oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics . Drug Metab Dispos 2008 ; 36 : 1828 - 1839 . 46 Quintas-Cardama A Kantarjian H O'Brien S . Pleural effusion in patients with chronic